Does Orilissa Reduce Endometriosis Pain?
Orilissa (elagolix) is FDA-approved for managing moderate to severe pain associated with endometriosis in premenopausal women. Clinical trials showed it significantly reduces dysmenorrhea (painful periods), non-menstrual pelvic pain, and dyspareunia (painful intercourse) compared to placebo. In two phase 3 studies (Elaris EM-1 and EM-2), involving over 1,600 women, 43-75% of patients on 150 mg or 200 mg daily doses reported at least a 30% pain reduction after 6 months, versus 19-27% on placebo.[1][2]
How Does Orilissa Work for Endometriosis?
Orilissa is a GnRH antagonist that lowers estrogen production by the ovaries, reducing endometrial tissue growth and inflammation that cause pain. It provides rapid symptom relief within weeks, unlike some hormonal therapies that take months. Dosing starts at 150 mg once daily for up to 24 months; 200 mg twice daily is for more severe cases, limited to 6 months due to bone density risks.[1]
What Do Clinical Trial Results Show?
- EM-1 trial: 75% on 200 mg achieved clinically meaningful dysmenorrhea relief vs. 27% placebo; 66% for non-menstrual pain vs. 48%.
- EM-2 trial: Similar results, with 43-55% overall responders.
Pain scores dropped by 30-50% on average. Benefits persisted through 12 months in extensions, but some patients needed add-on NSAIDs.[2][3]
Common Side Effects and Risks
Hot flashes (up to 46%), headaches (17%), and nausea (10%) are frequent. It decreases bone density (1-3% loss over 6-24 months), so DEXA scans are recommended for long-term use. Not for women planning pregnancy soon, as it suppresses ovulation.[1][4] Suicidal thoughts occurred in <1%, prompting boxed warnings.
How Does It Compare to Other Treatments?
| Treatment | Pain Reduction | Key Differences |
|-----------|---------------|-----------------|
| Orilissa | 30-75% responders | Oral, fast-acting; bone risks limit duration |
| Lupron (GnRH agonist) | Similar efficacy | Injections; more profound hypoestrogenism, higher bone loss |
| Visanne (dienogest) | 50-70% | Progestin-only; fewer hot flashes, longer use OK |
| Combined OCP | 20-40% | Milder relief; no bone risks |
Orilissa outperforms placebo more consistently in trials but costs $800-1,000/month without insurance.[3][5]
Who Responds Best and When to Expect Relief?
Best for women with severe dysmenorrhea unresponsive to NSAIDs or OCPs. Relief starts in 1-2 months, peaks at 3-6. Non-responders (20-30%) may switch to surgery or other hormones. Not curative—pain often returns after stopping.[2]
Is It Still Protected by Patents?
Orilissa's key patents expire in 2031-2033 in the US, with no generics approved yet. Check DrugPatentWatch.com for updates on challenges or Paragraph IV filings.[6]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210561s000lbl.pdf
[2] NEJM Study (2017): https://www.nejm.org/doi/full/10.1056/NEJMoa1700089
[3] Lancet Study (2018): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31187-7/fulltext
[4] AbbVie Safety Data: https://www.orilissa.com/
[5] GoodRx Pricing: https://www.goodrx.com/orilissa
[6] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/ORILISSA